Related Experiment Video

Updated: Sep 26, 2026

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
14:39

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

Clinicopathologic features of hypertrophic cardiomyopathy managed by cardiac transplantation

J Shirani1, B J Maron, R O Cannon

  • 1Pathology Branche, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.

The American Journal of Cardiology
|August 15, 1993
PubMed

Insights

Cardiac transplantation offers a survival benefit for patients with end-stage hypertrophic cardiomyopathy. This study shows improved functional outcomes in survivors post-transplant.

Area of Science:

  • Cardiology
  • Cardiovascular Surgery
  • Transplantation Medicine

Background:

  • Hypertrophic cardiomyopathy (HCM) can lead to severe congestive heart failure.
  • Cardiac transplantation is a potential treatment for end-stage HCM.
  • Understanding pre-transplant characteristics and post-transplant outcomes is crucial.

Purpose of the Study:

  • To review clinical data of patients undergoing cardiac transplantation for hypertrophic cardiomyopathy.
  • To evaluate the indications, pre-transplant physiological changes, and post-transplant outcomes.

Main Methods:

  • Review of clinical records, electrocardiographic, echocardiographic, hemodynamic, and radionuclide data.
  • Analysis of explanted hearts from 10 cardiac transplant recipients with hypertrophic cardiomyopathy.
  • Longitudinal assessment of hemodynamic and functional parameters pre- and post-transplantation.

Main Results:

  • Nine patients received transplants for severe congestive heart failure; one for syncope.
  • Pre-transplant, these patients showed increased pulmonary artery wedge pressure, decreased ejection fraction, and ventricular dilation.
  • Post-transplant, 6 of 10 patients survived long-term (mean 39 months) in functional class I or II.

Conclusions:

  • Cardiac transplantation can be a viable option for carefully selected patients with end-stage hypertrophic cardiomyopathy.
  • Long-term survival and improved functional capacity are achievable after transplantation.
  • Explanted hearts often showed ventricular dilation and scarring, suggesting advanced disease progression.

More Related Videos

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

A Surgical Method for Subvalvular Structure Intervention Through a Transaortic Approach in Normal Bama Pigs07:24

A Surgical Method for Subvalvular Structure Intervention Through a Transaortic Approach in Normal Bama Pigs

Published on: March 13, 2026

Related Concept Videos

Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...